LY3209590 for Type 2 Diabetes in Children
What You Need to Know Before You Apply
What is the purpose of this trial?
The main purpose of this study is to evaluate how much of LY3209590 gets into the blood stream after a single dose and how long it takes the body to remove it in pediatric participants with Type 2 Diabetes Mellitus (T2DM). The study will last for approximately 100 days.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but it does mention that participants should not have used insulin for at least 3 months before the study. If you are on insulin, you would need to stop it before joining the trial.
Is LY3209590 (Insulin efsitora alfa) safe for use in humans?
What makes the drug LY3209590 unique for treating type 2 diabetes in children?
LY3209590, also known as insulin efsitora alfa, is unique because it is designed for once-weekly administration, unlike most other insulins that require daily injections. This drug combines a novel insulin variant with a human protein component, potentially offering more convenience and improved adherence for patients.12567
What data supports the effectiveness of the drug LY3209590 for Type 2 Diabetes in children?
Who Is on the Research Team?
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Are You a Good Fit for This Trial?
This clinical trial is for children and teenagers who have Type 2 Diabetes Mellitus. Participants will be involved in the study for about 100 days to see how their bodies handle a single dose of a new diabetes medication, LY3209590.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single subcutaneous dose of LY3209590
Follow-up
Participants are monitored for safety and pharmacokinetics after the single dose
What Are the Treatments Tested in This Trial?
Interventions
- LY3209590
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University